Literature DB >> 1730487

Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.

C O Tacket1, D M Hone, R Curtiss, S M Kelly, G Losonsky, L Guers, A M Harris, R Edelman, M M Levine.   

Abstract

Three attenuated Salmonella typhi strains have been constructed by introducing deletions in aroC and aroD or deletions in cya and crp into one of two wild-type parent strains, Ty2 or ISP1820. These mutant strains were designated CVD 906 (ISP1820 delta aroC delta aroD), CVD 908 (Ty2 delta aroC delta aroD), and chi 3927 (Ty2 delta cya delta crp). Two studies were conducted with 36 healthy adult inpatient volunteers to determine in a double-blind fashion the safety and immunogenicity of approximately 5 x 10(4) and 5 x 10(5) CFU of each of these three vaccine candidates given as a single dose. No statistically significant difference in the incidence of reactions among vaccinees was observed. Fever (oral temperature greater than or equal to 38.2 degrees C) occurred in 2 of 12 volunteers who received CVD 906, in 0 of 12 who received CVD 908, and in 1 of 12 who received chi 3927. Vaccine bacteremia without symptoms occurred in 1 of 12 vaccinees who received CVD 906, in 0 of 12 who received CVD 908, and in 2 of 12 who received chi 3927. Overall, 19 (53%) of 36 vaccinees developed immunoglobulin G antibody to S. typhi lipopolysaccharide after vaccination, with no statistically significant differences in the rate of seroconversion among volunteers in the three groups. We conclude that defined mutations in the aromatic biosynthetic pathway and in the cyclic AMP global regulatory system attenuate S. typhi. Mutant strains CVD 906, CVD 908, and chi 3927 are highly (and approximately equally) immunogenic but possibly differ in their propensity to induce fever. Further studies are needed to document the apparent relative safety of CVD 908 as a typhoid vaccine and as a vaccine carrier of foreign antigens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730487      PMCID: PMC257661          DOI: 10.1128/iai.60.2.536-541.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines.

Authors:  S K Hoiseth; B A Stocker
Journal:  Nature       Date:  1981-05-21       Impact factor: 49.962

2.  Typhoid tonsillitis.

Authors:  P C Johnson
Journal:  JAMA       Date:  1980-07-25       Impact factor: 56.272

3.  A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans.

Authors:  D M Hone; S R Attridge; B Forrest; R Morona; D Daniels; J T LaBrooy; R C Bartholomeusz; D J Shearman; J Hackett
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

4.  Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a.

Authors:  C O Tacket; B Forrest; R Morona; S R Attridge; J LaBrooy; B D Tall; M Reymann; D Rowley; M M Levine
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

5.  Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei.

Authors:  L Van de Verg; D A Herrington; J R Murphy; S S Wasserman; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

6.  Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans.

Authors:  M M Levine; D Herrington; J R Murphy; J G Morris; G Losonsky; B Tall; A A Lindberg; S Svenson; S Baqar; M F Edwards
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

7.  Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves.

Authors:  B P Smith; M Reina-Guerra; S K Hoiseth; B A Stocker; F Habasha; E Johnson; F Merritt
Journal:  Am J Vet Res       Date:  1984-01       Impact factor: 1.156

8.  Salmonella typhimurium infection in calves: protection and survival of virulent challenge bacteria after immunization with live or inactivated vaccines.

Authors:  J A Robertsson; A A Lindberg; S Hoiseth; B A Stocker
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

9.  Aromatic-dependent "Salmonella sp." as live vaccine in mice and calves.

Authors:  B A Stocker; S K Hoiseth; B P Smith
Journal:  Dev Biol Stand       Date:  1983

10.  Immunogenicity of Ty21a attenuated "Salmonella typhi" given with sodium bicarbonate or in enteric-coated capsules.

Authors:  R Black; M M Levine; C Young; J Rooney; S Levine; M L Clements; S O'Donnell; T Hugues; R Germanier
Journal:  Dev Biol Stand       Date:  1983
View more
  65 in total

1.  Vaccines against gut pathogens.

Authors:  P Mastroeni; F Bowe; R Cahill; C Simmons; G Dougan
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

2.  Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity.

Authors:  Qingke Kong; David A Six; Kenneth L Roland; Qing Liu; Lillian Gu; C Michael Reynolds; Xiaoyuan Wang; Christian R H Raetz; Roy Curtiss
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

Review 3.  Bacterial infectious disease control by vaccine development.

Authors:  Roy Curtiss
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 4.  Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens.

Authors:  L Cárdenas; J D Clements
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

5.  Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans.

Authors:  A K Turner; T D Terry; D A Sack; P Londoño-Arcila; M J Darsley
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

6.  Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.

Authors:  J Y Wang; M F Pasetti; F R Noriega; R J Anderson; S S Wasserman; J E Galen; M B Sztein; M M Levine
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 7.  Live attenuated vaccines for invasive Salmonella infections.

Authors:  Sharon M Tennant; Myron M Levine
Journal:  Vaccine       Date:  2015-04-19       Impact factor: 3.641

8.  Role of RpoS in fine-tuning the synthesis of Vi capsular polysaccharide in Salmonella enterica serotype Typhi.

Authors:  Javier Santander; Soo-Young Wanda; Cheryl A Nickerson; Roy Curtiss
Journal:  Infect Immun       Date:  2006-12-18       Impact factor: 3.441

9.  Comparison of abilities of Salmonella enterica serovar typhimurium aroA aroD and aroA htrA mutants to act as live vectors.

Authors:  M Roberts; S Chatfield; D Pickard; J Li; A Bacon
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

10.  Immune responses to novel Escherichia coli and Salmonella typhimurium vectors that express colonization factor antigen I (CFA/I) of enterotoxigenic E. coli in the absence of the CFA/I positive regulator cfaR.

Authors:  S Wu; D W Pascual; J L VanCott; J R McGhee; D R Maneval; M M Levine; D M Hone
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.